Rocco Sgobbo

Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT.

PineBridge Global Funds-Asia ex Japan Small Cap Equity Fund provides investment services. It invests in companies in the ''Asian Region'' countries including Hong Kong, India, Indonesia, Malaysia, Pakistan, China, Philippines, Singapore, Sri Lanka, Taiwan, and Thailand. The company was incorporated on 15th December, 1993 and is headquartered in Dublin, Ireland.

PineBridge Global Funds - Asia Balanced Fund provides investment services. It is an investment company with variable capital under the European Communities Regulations, 2003. The fund invests its total assets in a broad range of equity and equity-related securities of Asian companies. It manages and provides investors with income and long-term capital appreciation through investment in equities, equity-related securities and debt securities of Asian issuers in the Asian Region. It was incorporated on 9th June, 1997 and is located in Dublin, Ireland.

PineBridge Greater China Equity Fund provided investment services. It was an open-ended investment company with variable capital under the European Communities Regulations, 2003. It was founded in October, 2002 and was headquartered in Dublin, Ireland.

Amgen Ltd. operates as a biotechnology firm. It engages in the research and development of human therapeutics to treat illnesses. The company was founded on March 1, 1989 and is headquartered in Cambridge, the United Kingdom.

ImaginAb, Inc. develops engineered antibody fragments for diagnostic imaging and novel therapeutic applications. It products offer actionable data to facilitate diagnosis of disease, inform better treatment decisions, and monitor response to therapy. The firm also offers a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT, and optical imaging systems. The company was founded by Christian P. Behrenbruch, Tove Olafsen, Anna M. Wu, and Robert E. Reiter in 2007 and is headquartered in Inglewood, CA.

Circle Pharma, Inc. provides biotechnology services. The company was founded by Matthew P. Jacobson and Scott Lokey in June 2014 and is headquartered in San Francisco, CA.

Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA.

Arrakis Therapeutics, Inc. operates as a biopharmaceutical company. It develops rna-targeted small molecule medicines focused on neurologic, cancer, and rare genetic diseases. The company was founded by Russell C. Petter, Alan E. Walts, Jennifer C. Petter and Raj Bhikhu Parekh in 2015 and is headquartered in Waltham, MA.

Hexagon Bio, Inc. operates as a data-driven biotechnology company. It engages in mining of fungal genome data for drugs. The company was founded by Maureen E. Hillenmeyer, Brian T. Naughton, Colin James Bell Harvey and Yi Tang and is headquartered in Menlo Park, CA.

A2 Biotherapeutics, Inc. operates as a biotechnology company. It develops medicines. The company was founded by Alexander Kamb, Michael Gallo and Paul Kang in 2018 and is headquartered in Westlake Village, CA.

MOMA Therapeutics, Inc. operates as a biotechnology firm. The company was founded by Dorothee Kern, Eva Nogales, Johannes Walter, and Timur Yusufzai and is headquartered in Cambridge, MA.

Exo Therapeutics, Inc. engages in production of drugs. It has developed a small-molecule enzyme inhibitor discovery platform that targets distal binding pockets of enzymes (exo-sites) that are not evolutionarily conserved. The company was founded by David R. Liu and Alan Saghatelian and is headquartered in Boston, MA.

Ambagon Therapeutics, Inc. provides healthcare services. It specializes in biotechnology. The company is headquartered in San Francisco, CA.

Alpha-9 Theranostics, Inc. operates as a clinical stage radiopharmaceutical company. It engages in developing breakthrough targeting agents for cancer imaging by positron emission tomography (PET) and therapy using targeted radioisotopes. The company was founded by Fran?ois B?nard, David Perrin, Kuo-Shyan Lin, and Ian McBeath and is headquartered in Vancouver, Canada.

IconOVir Bio, Inc. is an American biotechnology company that operates in the field of life sciences. The company was founded in 2018 by Arie S. Belldegrun, Ben Stone. The CEO is Mark A. McCamish.

Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022.

Alterome Therapeutics, Inc. is a precision oncology biotech that develops alteration-specific therapeutics to address high-value and validated oncogenic drivers. The company is based in San Marcos, CA. The company is led by seasoned R&D leaders with a history of developing marketed oncology small molecule drugs. The company's mission is to discover precise therapies and inspire hope for individuals affected by cancer. The CEO of the company is Eric A. Murphy.

Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts.